BioAtla, Inc. (BCAB) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
BioAtla, Inc.
Address
11085 Torreyana Road
San Diego, CA 92121
United States of America (the)
Phone
858 558 0708
Website
Sector
Healthcare
Industry
Biotechnology
Employees
41
First IPO Date
December 16, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Jay Short | Co-Founder, Chief Executive Officer & Chairman | 734,820 | 1958 |
| Christian Vasquez | CFO, CAO, Controller & Corporate Secretary | 408,745 | 1976 |
| Eric L. Sievers | Chief Medical Officer | 530,630 | 1964 |
| Gerhard Frey | Senior Vice President of Technology Development | 0 | N/A |
| Sheri Lydick | Chief Commercial Officer | 0 | N/A |
| Lisa Pelton | Accounting Manager | 0 | N/A |
| Susie Melody | Senior Vice President of Human Resources | 0 | N/A |
| Cathy Chang | Senior Vice President of Research & Development | 0 | N/A |
| Monica Sullivan | Senior Vice President of Intellectual Property & Contracts | 0 | N/A |
Description
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
